Hoffmann-La Roche To Rationalize In Germany
The German subsidiary of Swiss company Hoffmann-La Roche, which posted strong growth in 1994, is to introduce more intensive rationalization measures to meet tougher international competition.
The chairman, Otto Maile, has been concerned over high production costs and has introduced a high level of automation as well as cutting out hierarchical structures. Mr Maile says further strenuous efforts in this direction are needed.
Around 50% of the 1.2 billion Deutschemarks ($876.8 million) turnover in 1994 came from products manufactured at the company's south German plant. Drug sales amounted to 600 million marks, vitamins and fine chemicals sales were 500 million marks and sales of diagnostics were 50 million marks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze